About Exmobiogenics
Exmobiogenics is a company based in India. The company has 9 employees. Exmobiogenics offers products and services including Cardiovascular Medicines and Respiratory Medicines.
- Headquarter India
- Employees 9
- SectorsHealthcare
- Email••••••••
- Social X
- Legal Name Exmo Biogenics Private Limited
- Date of Incorporation 25 Feb, 2013
- Jurisdiction Thrissur, Kerala, India
- Annual Revenue₹15.78 Cr
FY 2025 · +5% YoY
- Net Profit₹69.5 Lakh
FY 2025 · 4% margin
- EBITDA₹1.83 Cr
FY 2025 · 12% margin
- Employee Count9
Associated legal entities of Exmobiogenics
Exmobiogenics operates through Exmo Biogenics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Exmo Biogenics Private Limited CIN U51397KL2013PTC033384 | Active | 25 Feb 2013 | Thrissur, Kerala | ₹15.8 Cr | 9 | 10 | View details |
Products & Services of Exmobiogenics
Exmobiogenics offers a comprehensive portfolio of products and services, including Cardiovascular Medicines and Respiratory Medicines.
Formulations for cardiovascular care are developed and supplied by Exmo Biogenics Pvt. Ltd. to address related health needs.
Formulations for respiratory conditions are provided by Exmo Biogenics Pvt. Ltd. as part of their product offerings.
Board of directors of Exmo Biogenics Private Limited (Exmobiogenics)
Exmo Biogenics Private Limited is the primary company behind Exmobiogenics. The board of Exmo Biogenics Private Limited currently have 10 directors; the longest-serving is Jayaprakasan Vellathery, appointed in 2013. 5 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Jayaprakasan Vellathery DIN 06476062 | Director | 25 Feb 2013 | 13 yrs 7 mo | Exmo Biogenics Private Limited |
| Anishkumar Manakkamveettil DIN 06479353 | Director | 25 Feb 2013 | 13 yrs 7 mo | Exmo Biogenics Private Limited |
| Murukesan Raveendran DIN 06479371 | Director | 25 Feb 2013 | 13 yrs 7 mo | Exmo Biogenics Private Limited |
| Saji Narayanan Nair DIN 06479381 | Director | 25 Feb 2013 | 13 yrs 7 mo | Exmo Biogenics Private Limited |
| Sundeep Keezhalath DIN 06478714 | Director | 25 Feb 2013 | 13 yrs 7 mo | Exmo Biogenics Private Limited |
| Viswanathan Subramanian DIN 06478697 | Managing Director | 25 Feb 2013 | 13 yrs 7 mo | Exmo Biogenics Private Limited |
| Beena Viswanathan DIN 08667756 | Director | 30 Dec 2019 | 6 yrs 9 mo | Exmo Biogenics Private Limited |
| Jisha Kallery DIN 08657628 | Director | 30 Dec 2019 | 6 yrs 9 mo | Exmo Biogenics Private Limited |
| Renju Raveendran Ushadevi DIN 08657606 | Director | 30 Dec 2019 | 6 yrs 9 mo | Exmo Biogenics Private Limited |
| Seema Jayaprakasan DIN 08668968 | Director | 30 Dec 2019 | 6 yrs 9 mo | Exmo Biogenics Private Limited |
Financials of Exmobiogenics
Figures of Exmo Biogenics Private Limited, the primary company behind Exmobiogenics, for FY 2025. Revenue was ₹15.78 Cr (+5% year on year). Net profit was ₹69.5 Lakh (4% margin). EBITDA was ₹1.83 Cr (12% margin). Revenue has grown at a compounded annual rate of +17% over three years and +19% over five years.
- ₹15.78 CrRevenue · FY 2025 · +5% YoY
- ₹69.5 LakhNet profit · 4% margin
- ₹1.83 CrEBITDA · 12% margin
- ₹55.5 LakhPaid-up capital
- 9Employees (provident fund records)
- +17%Revenue CAGR, 3 years
- +19%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Exmo Biogenics Private Limited are on its company page.
Detailed financial statements for Exmobiogenics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Exmobiogenics
10 companies that operate in the same segment as Exmobiogenics (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Exmobiogenics
Exmobiogenics is headquartered in India.
Exmobiogenics has 9 employees.
The primary company behind Exmobiogenics, Exmo Biogenics Private Limited, reported revenue of ₹15.78 Cr for FY 2025, up 5% year on year.
Exmo Biogenics Pvt. Ltd. is positioned as a pharmaceutical entity that strives to achieve fast growth within the Indian market. Quality-driven and technologically advanced formulations are utilized by the company to excel in life care initiatives. A commitment to providing innovative, effective, safe, and affordable medicines is demonstrated, aiming to contribute to a healthier future for humanity. Products encompass categories such as cardiovascular, respiratory, anti-infective agents, immunosuppressants, supplements, pain management, wound healing, antiulcerants, and antidiabetics. Operations are based in Mumbai, where efforts are directed towards meeting global health needs through reliable pharmaceutical solutions.
Exmobiogenics offers Cardiovascular Medicines and Respiratory Medicines.
Exmobiogenics operates through Exmo Biogenics Private Limited.
The legal entities of Exmobiogenics currently have 10 directors, including Jayaprakasan Vellathery, Anishkumar Manakkamveettil, Murukesan Raveendran and others.